TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jazz Pharmaceuticals ( (JAZZ) ) has issued an announcement.
On November 17, 2025, Jazz Pharmaceuticals announced positive results from the Phase 3 HERIZON-GEA-01 trial, which evaluated Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without tislelizumab, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. The trial demonstrated statistically significant improvements in progression-free survival and overall survival compared to the standard treatment, trastuzumab plus chemotherapy. These findings suggest that Ziihera could become the new standard of care for this patient group, and Jazz Pharmaceuticals plans to submit a supplemental Biologics License Application in the first half of 2026.
The most recent analyst rating on (JAZZ) stock is a Buy with a $230.00 price target. To see the full list of analyst forecasts on Jazz Pharmaceuticals stock, see the JAZZ Stock Forecast page.
Spark’s Take on JAZZ Stock
According to Spark, TipRanks’ AI Analyst, JAZZ is a Neutral.
Jazz Pharmaceuticals’ overall score is driven by strong earnings call performance and positive technical indicators, offset by profitability challenges and valuation concerns. The company’s strategic advancements and pipeline developments are promising, but financial performance needs improvement.
To see Spark’s full report on JAZZ stock, click here.
More about Jazz Pharmaceuticals
Jazz Pharmaceuticals is a biopharmaceutical company that focuses on developing and commercializing products for unmet medical needs in neuroscience, oncology, and sleep medicine. The company is involved in the development of zanidatamab-hrii, a bispecific HER2-directed antibody, for treating HER2-positive cancers.
Average Trading Volume: 731,350
Technical Sentiment Signal: Buy
Current Market Cap: $8.57B
See more data about JAZZ stock on TipRanks’ Stock Analysis page.